Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EyePoint Pharmaceuticals ( (EYPT) ) just unveiled an announcement.
On May 27, 2025, EyePoint Pharmaceuticals announced the completion of patient enrollment in the Phase 3 LUGANO clinical trial for DURAVYU, a treatment for wet age-related macular degeneration (wet AMD). This milestone was achieved with over 400 patients enrolled in seven months, marking one of the fastest enrollments for a Phase 3 trial in wet AMD. The trial’s rapid progress reflects strong interest from both patients and physicians, highlighting the commercial potential of DURAVYU. The LUGANO trial, along with the ongoing LUCIA trial, aims to assess the efficacy and safety of DURAVYU, with topline data expected in mid-2026. The trials are designed to evaluate the potential of DURAVYU to transform treatment paradigms for wet AMD, offering a sustained-release option that could reduce treatment burdens and improve patient compliance.
The most recent analyst rating on (EYPT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.
Spark’s Take on EYPT Stock
According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.
EyePoint Pharmaceuticals shows potential in its clinical developments and maintains a strong cash position. However, significant financial challenges in profitability, cash flow management, and a negative technical outlook weigh heavily on the overall stock score.
To see Spark’s full report on EYPT stock, click here.
More about EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases. The company utilizes its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. EyePoint’s lead product candidate, DURAVYU, is an investigational treatment for VEGF-mediated retinal diseases, currently in Phase 3 clinical trials for wet age-related macular degeneration and has completed a Phase 2 trial for diabetic macular edema. The company is headquartered in Watertown, Massachusetts.
Average Trading Volume: 770,292
Technical Sentiment Signal: Sell
Current Market Cap: $390.9M
For detailed information about EYPT stock, go to TipRanks’ Stock Analysis page.